Grifols (GRFS) Change in Intangibles (2010 - 2020)
Grifols (GRFS) posted Change in Intangibles of -$28.9 million for Q1 2020, up 60.41% quarter-over-quarter from -$73.0 million in Q4 2019, and down 54.18% year-on-year from -$63.1 million in Q2 2019.
Grifols (GRFS) Change in Intangibles (2010 - 2020) Analysis & Trends
Grifols (GRFS) has reported Change in Intangibles for 10 consecutive years, with -$28.9 million the latest figure, recorded in Q1 2020.
- Change in Intangibles for Q1 2020 came in at -$28.9 million, down 54.18% year-over-year; the trailing twelve-month figure through Mar 2020 was -$73.9 million (down 373.3% YoY), and the FY2021 annual result was -$77.5 million, up 17.67% from the prior year.
- Change in Intangibles was -$28.9 million for Q1 2020 at Grifols, up from -$73.0 million in the prior quarter.
- Over five years, Change in Intangibles peaked at $46.8 million in Q4 2018 and troughed at -$73.0 million in Q4 2019.
- Average Change in Intangibles over 5 years is -$12.4 million, with a median of -$7.3 million recorded in 2017.
- Year-over-year, Change in Intangibles plunged 854.1% in 2016 and jumped 364.21% in 2018.
- Over 5 years, Change in Intangibles stood at -$59.4 million in 2016, then soared by 150.66% to $30.1 million in 2017, then soared by 55.34% to $46.8 million in 2018, then slumped by 256.18% to -$73.0 million in 2019, then jumped by 60.41% to -$28.9 million in 2020.
- Per Business Quant data, the three most recent Change in Intangibles figures were -$28.9 million in Q1 2020, -$73.0 million in Q4 2019, and -$18.8 million in Q1 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -991.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | -461.00 Mn |
| 10 | Grifols | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -28.91 Mn |
| Mar 31, 2020 | -28.91 Mn |
| Dec 31, 2019 | -73.03 Mn |
| Dec 31, 2019 | -73.03 Mn |
| Mar 31, 2019 | -18.75 Mn |
| Mar 31, 2019 | -18.75 Mn |
| Dec 31, 2018 | 46.76 Mn |
| Dec 31, 2018 | 46.76 Mn |
| Jun 30, 2018 | -62.47 Mn |
| Jun 30, 2018 | -62.47 Mn |
| Mar 31, 2018 | 18.84 Mn |
| Mar 31, 2018 | 18.84 Mn |
| Dec 31, 2017 | 30.10 Mn |
| Dec 31, 2017 | 30.10 Mn |
| Jun 30, 2017 | 18.45 Mn |
| Jun 30, 2017 | 18.45 Mn |
| Mar 31, 2017 | 4.06 Mn |
| Mar 31, 2017 | 4.06 Mn |
| Dec 31, 2016 | 35.46 Mn |
| Dec 31, 2016 | 35.46 Mn |